Anatara's CEO Steve Lydeamore has been invited to present at the Pitt Street Research Life Sciences Conference on the 28th November in Sydney. Any investors interested in attending these presentations are invited to reach out.
Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore is interviewed by ABN Newswire, and talks about the human trials as well as the product pipeline for next year.
As Anatara moves forward, the Board is confident in the knowledge that a substantial market opportunity for Detach(R) remains, with more pressure than ever on producers to reduce their antibiotic use and find suitable alternatives which minimise illnesses, such as scour, on farms.
Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today released its quarterly cashflow report for the period ending 30 September 2019 (Q1 FY20).
Regeneus Ltd (ASX:RGS) is a Sydney Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell cell-based therapies to address significant unmet medical needs in the human health markets.
Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, will present today at the 10th Annual Australian Microcap Investment Conference, held in Melbourne, VIC.
Anatara Lifesciences CEO Steve Lydeamore sat down with Tim Boreham this week for Stockhead's new podcast series, "The Health Kick".
